Panbela Therapeutics, Inc. · OTC:PBLA
Panbela Therapeutics — Investor Presentation (January 2022)
22 slides from Panbela Therapeutics's investor presentation, January 2022
Slide 1: Company Overview
Company Overview January, 2022 Last modified on 1/3/22
Slide 2: Cautionary Statements
Cautionary Statements Certain statements in this presentation are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are provided under the protection of the safe harbor for forward-looking statements provided by that Act. Forward-looking statem
Slide 3: Company Highlights
Company Highlights New Therapeutic Class For Solid Tumors ― Developing small molecule polyamine metabolic inhibitors with tumor and organ-specific preferential uptake ― Multiple cancer types with known elevated polyamine levels represent potential targets ― Novel Trojan Horse polyamine metabolic inh
Slide 4: Panbela Leadership Team and Board of Directors
Panbela Leadership Team and Board of Directors Collectively developed 10 FDA-approved therapies generating billions in sales Leadership Team Board of Directors Jennifer K. Simpson, PhD, MSN, CRNP Michael T. Cullen, MD, MBA, ABIM President & CEO Jennifer K. Simpson, PhD, MSN, CRNP Susan Horvath, CP
Slide 5: Pancreatic Cancer: a Major Unmet Medical Need
Pancreatic Cancer: a Major Unmet Medical Need Globally, the number of deaths caused by, and incidence of, pancreatic cancer has more than doubled from 1990 to 2017 5-Year Survival Rate (U.S.) Deaths in the U.S. (Thousands) 100% 98% 160 90% Lowest survival rate 3rd leading cause 136 among major can
Slide 6: Objective Response Rate Comparison Among Prior PDAC Trials
Objective Response Rate Comparison Among Prior PDAC Trials In addition to strong ORR results, 70% of SBP-101 patients presented CA 19-9 biomarker reductions of greater than 60% MPACT Registration Trial Halozyme Cohort 4 + P1b Interim P3 P3 Ongoing Approved and SOC Discontinued 60% 70% 70% 48% +25p
Slide 7: Increased Polyamine Levels Can Enhance the Malignant Potential of Cancer Cells
Increased Polyamine Levels Can Enhance the Malignant Potential of Cancer Cells and May Decrease Anti-Tumor Immunity Many tumors maintain greatly elevated levels of polyamines to support their rapid growth and survival ‒ Of all human tissues, the pancreas has the highest level of native spermidine
Slide 8: SBP-101 MOA (Trojan Horse): Synthetic Polyamine Analogue
SBP-101 MOA (Trojan Horse): Synthetic Polyamine Analogue SBP-101 is a synthetic analogue of spermine being designed to exploit the self-regulating nature of polyamine metabolism SBP-101 preferentially accumulates in tumor cells and downregulates the polyamine metabolic pathway, lowering producti
Slide 9: Area of Future Exploration: SBP-101 Combined with IOs
Area of Future Exploration: SBP-101 Combined with IOs Historical clinical trials using IO agents have been unsuccessful A potential hypothesis is that excess polyamines, especially spermine, insulate the tumor microenvironment from immune cells SBP-101 is a synthetic analogue of spermine, whic
Slide 10: Significant SBP-101 Polyamine Metabolic Inhibitor Pipeline Expansion Opportunity
Significant SBP-101 Polyamine Metabolic Inhibitor Pipeline Expansion Opportunity Upregulated polyamine metabolism is also a phenotypic change caused by certain oncogenic mutations, creating potential for future patient stratification strategies in other cancers Discovery Preclinical IND Ready Phase
Slide 11: SBP-101: Human Tumor Inhibition in Pre-Clinical Studies
SBP-101: Human Tumor Inhibition in Pre-Clinical Studies Near Complete Tumor Inhibition in Mice(1) Reduction of Tumor Volume in Mice(2) 1400 8,000 Untreated Control 7,199 1200 7,000 SBP-101 reduction in tumor volume vs. control SBP-101 15 mg/kg 6,000 and vs. Gemcitabine alone 1000 Mean Tumor Burden (
Slide 12: SBP-101 Shows Greater Inhibition of Human PDA Growth Than Standard of Care
SBP-101 Shows Greater Inhibition of Human PDA Growth Than Current Standard of Care (Gem + Nab) in an in vitro Study SBP-101 Demonstrates Superior and Additive Efficacy in vitro Gemcitabine + Nab-Paclitaxel SBP-101 Gemcitabine + Nab-Paclitaxel + SBP-101 100 90 80 70 60 % Inhibition 50 40 30 20 10 0 A
Slide 13: SBP-101 Phase 1 PDA Study Design
SBP-101 Phase 1 PDA Study Design* Overview Design Open-label P1A/1B study to assess safety, tolerability and PK Dose Enrolled Dosing Schedule when combined with Nab-Paclitaxel and Gemcitabine Cohort 1 (n = 4) 0.2 mg/kg only Identify P2 dose and schedule and assess preliminary efficacy of 3-drug
Slide 14: Clinical Importance of CA 19-9 Biomarker
Clinical Importance of CA 19-9 Biomarker Carbohydrate antigen (CA) 19-9 is a type of antigen found in the blood that is often elevated in pancreatic disease Studies have suggested that decreases in CA 19-9 levels are correlated with improved prognosis; ≥60-75% declines in CA 19-9 levels correlat
Slide 15: CA 19-9 Biomarker and Survival Benefit Correlation
CA 19-9 Biomarker and Survival Benefit Correlation Patients in the MPACT study (Phase III Gem+Nab) whose CA 19-9 levels decreased saw an approximate 5-month incremental median survival benefit (P=.001) compared to patients with unchanged or increased CA 19-9 levels Greatest survival benefit obse
Slide 16: Maximum CA 19-9 Percent Change From Baseline by Response
Interim Cohort 4 + P1B CA 19-9 Positive Biomarker Data 70% of subjects had a maximum CA 19-9 decrease greater than 60% 90% of subjects had a decrease in CA 19-9 levels CA 19-9 tumor marker often released by 1 pancreatic cancer cells 0.8 Maximum CA 19-9 Percent Change From Baseline by 0.6 0.4 Pat
Slide 17: SBP-101 Interim ORR Data
SBP-101 Interim ORR Data 3.1x the response rate of Gemcitabine & Nab-Paclitaxel in Cohort 2 SBP-101 Well 2.1x the response rate in Cohort 4 + P1B Tolerated in 2.1x the disease control rate of Gemcitabine & Nab-Paclitaxel in Cohort 2 Combination with 1.5x the disease control rate in Cohort 4
Slide 18: Interim Response Rate by Patient
Interim Response Rate by Patient N = 29 across Cohort 4 and P1B (0.4 mg/kg) N = 7 across Cohort 2 (0.4 mg/kg) ORR: 48% 71% partial response (5 of 7) 3% Complete Response (1 of 29)(1) 29% stable disease (2 of 7) 45% Partial Response (13 of 29) (2) 34% stable disease (10 of 29) 2 pat
Slide 19: Interim Results
Interim Results Gemcitabine (G, Gemzar, Eli Lilly) & Nab-Paclitaxel (A, Abraxane, Celgene): Standard pancreatic cancer Rx combination Grade 3-4 neutropenia 38% Grade 3-4 thrombocytopenia 13% Grade 3-4 peripheral neuropathy 17% SBP-101 No added neutropenia, thrombocytopenia, or neuropat
Slide 20: Cash Balance and Capitalization
Cash Balance and Capitalization Cash Balance as of September 30, 2021 $14,072,000 Capitalization Table Common Stock Outstanding as of September 30, 2021 13,434,152 Stock Options @ $5.87 WAEP 2,489,136 Restricted Stock Units Outstanding 16,185 Warrants @ $4.59 WAEP 5,109,501 Fully Diluted Shares Outs
Slide 21: Milestones
Milestones 2022 ► First Patient Enrolled in randomized phase 2 study (1Q’22) ► ASCO GI Poster Presentation (1Q – January) ► First Patient Enrolled – Neoadjuvant Pancreatic Trial (1Q'22) ► Final Data from phase 1 trial (1H'22) ► Initiate Ovarian Cancer Clinical Program(1H’22) Panbela Therapeutics 21
Slide 22: SBP-101 Summary
SBP-101 Summary Unique dual-attack MOA is synergistic with other agents, potentially enhancing anti-tumor response Favorable safety & tolerability profile and subcutaneous administration in clinical studies to date supports potential ease of use Interim data from Phase 1a/1b trial to be presented at
Panbela Therapeutics — Investor Presentation (January 2022) on 6ix